Schrödinger Inc.’s stock soared 9% early Tuesday, after the company said it has entered a multi-year collaboration agreement ...

Schrödinger (NASDAQ:SDGR) shares traded higher on Tuesday despite reporting lower-than-expected Q3 2024 financials after the ...

Hidradenitis suppurativa (HS) is a relatively common skin disease, affecting as many as one percent of people worldwide. But ...

Novartis is paying $150 million for a closer look at Schrödinger’s catalog of programs. The Big Pharma will work with Schrödinger to advance some of the computing-enabled R&D shop’s discovery programs ...

Schrödinger partners with Novartis for advanced computational drug discovery. Q3 revenue rose 10% in software, though total ...

Schrodinger (SDGR) today announced a research collaboration and license agreement with Novartis (NVS) to advance multiple development ...

Novartis AG's revenue and core EPS topped analysts' expectations in Q3. Click here to read more on the analysis of NVS stock ...

Novartis raised its 2024 earnings guidance for the third time on Tuesday, buoyed by wider use of its prescription drugs, but ...

Novartis (NVS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Steve Scala from ...

Siemens Healthineers(XTRA:SHL) has reported a strong financial performance with a notable increase in earnings and sales for the fiscal year 2024, reflecting the company's effective business ...

Novartis exceeded analyst expectations in the third quarter, driven primarily by the strong U.S. sales of Cosentyx, as well ...

Novartis posted third-quarter results that beat analysts' estimates and raised its full-year outlook, buoyed by strong sales ...